Literature DB >> 25056375

Evidence for molecular differences in prostate cancer between African American and Caucasian men.

Francesca Khani1, Juan Miguel Mosquera2, Kyung Park1, Mirjam Blattner1, Catherine O'Reilly1, Theresa Y MacDonald1, Zhengming Chen3, Abhishek Srivastava4, Ashutosh K Tewari4, Christopher E Barbieri4, Mark A Rubin5, Brian D Robinson6.   

Abstract

PURPOSE: The aim of this study was to compare the frequency of ERG rearrangement, PTEN deletion, SPINK1 overexpression, and SPOP mutation in prostate cancer in African American and Caucasian men. EXPERIMENTAL
DESIGN: Dominant tumor nodules from radical prostatectomy specimens of 105 African American men (AAM) were compared with 113 dominant nodules from Caucasian men (CaM). Clinical and pathologic characteristics of the two groups were similar. SPINK1 overexpression was evaluated by immunohistochemistry, ERG rearrangement and PTEN deletion by FISH, and SPOP mutation by Sanger sequencing.
RESULTS: ERG rearrangement was identified in 48 of 113 tumors (42.5%) in CaM and 29 of 105 tumors (27.6%) in AAM (P = 0.024). PTEN deletion was seen in 19 of 96 tumors (19.8%) in CaM and 7 of 101 tumors (6.9%) in AAM (P = 0.011). SPINK1 overexpression was present in 9 of 110 tumors (8.2%) in CaM and 25 of 105 tumors (23.4%) in AAM (P = 0.002). SPOP mutation was identified in 8 of 78 (10.3%) tumors in CaM and 4 of 88 (4.5%) tumors in AAM (P = 0.230). When adjusted for age, body mass index, Gleason score, and pathologic stage, ERG rearrangement and SPINK1 overexpression remain significantly different (P = 0.018 and P = 0.008, respectively), and differences in PTEN deletion and SPOP mutation approach significance (P = 0.061 and P = 0.087, respectively).
CONCLUSIONS: Significant molecular differences exist between prostate cancers in AAM and CaM. SPINK1 overexpression, an alteration associated with more aggressive prostate cancers, was more frequent in AAM, whereas ERG rearrangement and PTEN deletion were less frequent in this cohort. Further investigation is warranted to determine whether these molecular differences explain some of the disparity in incidence and mortality between these two ethnic groups. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25056375      PMCID: PMC4167562          DOI: 10.1158/1078-0432.CCR-13-2265

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  48 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

Review 2.  Pten inactivation and the emergence of androgen-independent prostate cancer.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

3.  Identification of a novel nuclear speckle-type protein, SPOP.

Authors:  Y Nagai; T Kojima; Y Muro; T Hachiya; Y Nishizawa; T Wakabayashi; M Hagiwara
Journal:  FEBS Lett       Date:  1997-11-24       Impact factor: 4.124

4.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.

Authors:  Sven Perner; Francesca Demichelis; Rameen Beroukhim; Folke H Schmidt; Juan-Miguel Mosquera; Sunita Setlur; Joelle Tchinda; Scott A Tomlins; Matthias D Hofer; Kenneth G Pienta; Rainer Kuefer; Robert Vessella; Xiao-Wei Sun; Matthew Meyerson; Charles Lee; William R Sellers; Arul M Chinnaiyan; Mark A Rubin
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

5.  Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.

Authors:  Annukka Paju; Kristina Hotakainen; Yue Cao; Timo Laurila; Virgil Gadaleanu; Akseli Hemminki; Ulf-Håkan Stenman; Anders Bjartell
Journal:  Eur Urol       Date:  2007-02-05       Impact factor: 20.096

6.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

Authors:  F Demichelis; K Fall; S Perner; O Andrén; F Schmidt; S R Setlur; Y Hoshida; J-M Mosquera; Y Pawitan; C Lee; H-O Adami; L A Mucci; P W Kantoff; S-O Andersson; A M Chinnaiyan; J-E Johansson; M A Rubin
Journal:  Oncogene       Date:  2007-01-22       Impact factor: 9.867

7.  Measurement of PTEN expression using tissue microarrays to determine a race-specific prognostic marker in breast cancer.

Authors:  Jerald Luke Winter; Bodiford L Stackhouse; Gregory B Russell; Timothy E Kute
Journal:  Arch Pathol Lab Med       Date:  2007-05       Impact factor: 5.534

Review 8.  Prostate cancer treatment outcome in blacks and whites: a summary of the literature.

Authors:  G A Alexander; O W Brawley
Journal:  Semin Urol Oncol       Date:  1998-11

9.  Role of PTEN gene in progression of prostate cancer.

Authors:  Gholamreza Pourmand; Abed-Ali Ziaee; Amir Reza Abedi; Abdolrasoul Mehrsai; Hossein Afshin Alavi; Ali Ahmadi; Hamid Reza Saadati
Journal:  Urol J       Date:  2007       Impact factor: 1.510

10.  The role of SPINK1 in ETS rearrangement-negative prostate cancers.

Authors:  Scott A Tomlins; Daniel R Rhodes; Jianjun Yu; Sooryanarayana Varambally; Rohit Mehra; Sven Perner; Francesca Demichelis; Beth E Helgeson; Bharathi Laxman; David S Morris; Qi Cao; Xuhong Cao; Ove Andrén; Katja Fall; Laura Johnson; John T Wei; Rajal B Shah; Hikmat Al-Ahmadie; James A Eastham; Scott E Eggener; Samson W Fine; Kristina Hotakainen; Ulf-Håkan Stenman; Alex Tsodikov; William L Gerald; Hans Lilja; Victor E Reuter; Phillip W Kantoff; Peter T Scardino; Mark A Rubin; Anders S Bjartell; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2008-06       Impact factor: 31.743

View more
  77 in total

1.  Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.

Authors:  Ramy A Abdelsalam; Ibrahim Khalifeh; Alan Box; Maria Kalantarian; Sunita Ghosh; Hatem Abou-Ouf; Tamara Lotfi; Mohammed Shahait; Nallasivam Palanisamy; Tarek A Bismar
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-30       Impact factor: 4.553

Review 2.  TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.

Authors:  Cindy Ke Zhou; Denise Young; Edward D Yeboah; Sally B Coburn; Yao Tettey; Richard B Biritwum; Andrew A Adjei; Evelyn Tay; Shelley Niwa; Ann Truelove; Judith Welsh; James E Mensah; Robert N Hoover; Isabell A Sesterhenn; Ann W Hsing; Shiv Srivastava; Michael B Cook
Journal:  Am J Epidemiol       Date:  2017-12-15       Impact factor: 4.897

3.  Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences.

Authors:  Walter Rayford; Alp Tuna Beksac; Jordan Alger; Mohammed Alshalalfa; Mohsen Ahmed; Irtaza Khan; Ugo G Falagario; Yang Liu; Elai Davicioni; Daniel E Spratt; Edward M Schaeffer; Felix Y Feng; Brandon Mahal; Paul L Nguyen; Robert B Den; Mark D Greenberger; Randy Bradley; Justin M Watson; Matthew Beamer; Lambros Stamatakis; Darrell J Carmen; Shivanshu Awasthi; Jonathan Hwang; Rachel Weil; Harri Merisaari; Nihal Mohamed; Leslie A Deane; Dimple Chakravarty; Kamlesh K Yadav; Kosj Yamoah; Sujit S Nair; Ashutosh K Tewari
Journal:  Commun Biol       Date:  2021-06-03

4.  RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression.

Authors:  Yongquan Wang; Jianghua Wang; Li Zhang; Omer Faruk Karatas; Longjiang Shao; Yiqun Zhang; Patricia Castro; Chad J Creighton; Michael Ittmann
Journal:  Cancer Res       Date:  2017-06-13       Impact factor: 12.701

Review 5.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

6.  A CD24-p53 axis contributes to African American prostate cancer disparities.

Authors:  Wei Liu; Yue Zhang; Shi Wei; Sejong Bae; Wei-Hsiung Yang; Gary J Smith; James L Mohler; Elizabeth T H Fontham; Jeannette T Bensen; Guru P Sonpavde; Guo-Yun Chen; Runhua Liu; Lizhong Wang
Journal:  Prostate       Date:  2020-03-13       Impact factor: 4.104

7.  PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Authors:  Carlos L Morais; Mehsati Herawi; Antoun Toubaji; Roula Albadine; Jessica Hicks; George J Netto; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan
Journal:  Prostate       Date:  2015-07-14       Impact factor: 4.104

8.  SPOP mutations in prostate cancer across demographically diverse patient cohorts.

Authors:  Mirjam Blattner; Daniel J Lee; Catherine O'Reilly; Kyung Park; Theresa Y MacDonald; Francesca Khani; Kevin R Turner; Ya-Lin Chiu; Peter J Wild; Igor Dolgalev; Adriana Heguy; Andrea Sboner; Sinan Ramazangolu; Haley Hieronymus; Charles Sawyers; Ashutosh K Tewari; Holger Moch; Ghil Suk Yoon; Yong Chul Known; Ove Andrén; Katja Fall; Francecsa Demichelis; Juan Miguel Mosquera; Brian D Robinson; Christopher E Barbieri; Mark A Rubin
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

9.  Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.

Authors:  Franklin W Huang; Juan Miguel Mosquera; Andrea Garofalo; Coyin Oh; Maria Baco; Ali Amin-Mansour; Bokang Rabasha; Samira Bahl; Stephanie A Mullane; Brian D Robinson; Saud Aldubayan; Francesca Khani; Beerinder Karir; Eejung Kim; Jeremy Chimene-Weiss; Matan Hofree; Alessandro Romanel; Joseph R Osborne; Jong Wook Kim; Gissou Azabdaftari; Anna Woloszynska-Read; Karen Sfanos; Angelo M De Marzo; Francesca Demichelis; Stacey Gabriel; Eliezer M Van Allen; Jill Mesirov; Pablo Tamayo; Mark A Rubin; Isaac J Powell; Levi A Garraway
Journal:  Cancer Discov       Date:  2017-05-17       Impact factor: 39.397

10.  A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Authors:  Thomas U Ahearn; Andreas Pettersson; Ericka M Ebot; Travis Gerke; Rebecca E Graff; Carlos L Morais; Jessica L Hicks; Kathryn M Wilson; Jennifer R Rider; Howard D Sesso; Michelangelo Fiorentino; Richard Flavin; Stephen Finn; Edward L Giovannucci; Massimo Loda; Meir J Stampfer; Angelo M De Marzo; Lorelei A Mucci; Tamara L Lotan
Journal:  J Natl Cancer Inst       Date:  2015-11-27       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.